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OBJECTIVES: To compare the efﬁ cacy and safety of a nifedipine sustained release 
(nifedipine SR), with ginkgo biloba extract as treatment for primary Raynaud’s phe-
nomenon in Korean. METHODS: ; Multi-centred, randomised, ﬂ exible dose and open 
study. A total of 134 patients with primary Raynaud’s phenomenon were selected from 
3 centers and randomly assigned to either the Nifedipine SR group (Group N) or the 
Ginkgo biloba extract group (Group G) in the ratio of 2:1. After a run-in period of 
two weeks, participants received treatment for eight weeks. Primary efﬁ cacy evaluation 
was any percent change of the Raynaud attack rate between the reference value before
treatment and after the 8-week treatment. A safety was also evaluated. RESULTS: ; 
Out of 134 patients with primary Raynaud’s phenomenon, 39 subjects dropped out
of the program during the selection period. Ninety-three subjects (70.5% of the origi-
nal pool) were randomly assigned, and 64 subjects (Group N: 42, Group G: 22) among 
the 93 completed this clinical trial. There were 24 male subjects (25.81%) and 69
female subjects(74.19%), and the average age of the subjects was 39.20 (Group N: 
37.67, Group G: 42.13). The percent change of the attack rate in Intention To Treat 
(ITT) group was 50.05% at 7 and 8 weeks after treatment in Group N, while it was 
just 31.02% in Group G (p-value  0.03). The improvement was shown to be much 
higher in Group N than in Group G. No difference in QOL items was found between
the two groups in this clinical trial. No signiﬁ cant adverse events occurred; severity 
of the adverse events incurred was mostly mild, and those adverse events were
improved without speciﬁ c treatment. CONCLUSIONS: Nifedipine SR was more effec-
tive pharmacotherapy than Ginkgo biloba for primary Raynaud’s phenomenon 
(Percent change of R : 50.1% vs. 31%). Both Nifedipine SR and Ginkgo biloba
showed tolerability without serious adverse events.
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OBJECTIVES: Aspirin may interact with ACE inhibitors to reduce their beneﬁ cial
effects in patients with heart failure. The objective of this retrospective cohort study
was to assess the risk of congestive heart failure (CHF) hospitalization in patients with
heart failure (HF) taking ACE inhibitors in a large national cohort of veterans.
METHODS: Exposure to aspirin was assessed between October 1, 2000 and Septem-
ber 30, 2001. Patients were characterized as prescribed: no aspirin, low-dose (a 81 mg)
aspirin, high-dose (81 mg) aspirin. Time to HF hospitalization in these selected 
patients was assessed between October 1, 2001 and September 30, 2002. Chi-square
tests, Kaplan-Meier plots and log-rank tests were employed for testing bivariate asso-
ciations. A multivariable Cox regression model was used to estimate the adjusted
hazard ratio for the risk of CHF hospitalization due to aspirin exposure after control-
ling for sociodemographic factors, comorbidities, comedications, and years with HF. 
RESULTS: The ﬁ nal study cohort consisted of 157,088 HF patients with a mean age
of 69.75 ( o 10.19) years. The crude HF hospitalization rates differed signiﬁ cantly
between the treatment groups (log-rank statistic for KM plot: p-value 0.001). In 
multivariate analysis of the association of aspirin use and hospitalization for CHF the 
use of both high-dose aspirin (HR 1.26, 95% CI 1.19–1.34) and low-dose aspirin (HR 
1.18, 95% CI 1.09–1.27) was associated with increased risk of CHF hospitalization
with no aspirin use as the reference group. The results remained the same for high-dose 
aspirin in case of patients: with both CHF and IHD, without IHD, age  65 years, 
age q 65 years and patients with Medication Possession Ratio (MPR) q 0.8. CONCLU-
SIONS: The theory of negative interaction between ACE inhibitors and aspirin may 
be true, but results must be interpreted with caution. Prospective studies would be
needed to investigate this interaction further.
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US BUDGET IMPACT OF INCREASING ASPIRIN USAGE FOR PRIMARY
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OBJECTIVES: Cardiovascular disease (CVD) is a leading cause of death in the US, 
but regular use of preventive low-dose aspirin has proven to be an effective way to
prevent CV events. The purpose of this study was to explore the potential economic
impact in the US if aspirin usage were to be increased in line with current clinical 
guidelines for primary and secondary prevention of CV events. METHODS: The 
risk proﬁ le of the US population was modeled using NHANES data and the Framing-
ham cardiovascular risk equations were applied to calculate risk for myocardial 
infarction, angina and stroke according to age and gender. Primary and secondary
prevention patient populations were considered separately. Using publicly available 
unit costs, a budget impact model calculated the annual impact of increased preventive 
aspirin usage considering adverse events and diminishing aspirin adherence over a 
ten-year time horizon. RESULTS: In a base population of 1,000,000 patients, imple-
mentation of current clinical guidelines would prevent an additional 1273 myocardial
infarctions, 2184 angina episodes and 565 strokes in primary prevention patients
and an additional 578 myocardial infarctions, and 607 strokes in secondary preven-
tion patients. Angina reduction was not assessed in secondary prevention patients.
This represents a total savings to the Managed Care Organization (MCO) of $84.9
million for primary prevention and $32.7 million for secondary prevention and addi-
tional out of pocket expense to patients of $32.1 million for primary prevention and 
$2.9 million for secondary prevention for the cost of aspirin. CONCLUSIONS: This 
model suggests that there is a strong economic case, both for payers as well as for 
society, to encourage aspirin use for patients at appropriate risk and per clinical
guidelines. It also provides an example of how minimizing costs does not necessarily 
have to imply rationing of care.
PCV32
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Han F1, Xiong X1, Tao L2, Xu P3, Liu S3
1China Health Insurance Research Association, Beijing, China, 2Johnson & Johnson Medical AP, 
Beijing, China, 3Johnson & Johnson Medical China, Beijing, China
OBJECTIVES: In China, increasing CHD patients accept PCI treatment, with about
40% GR annually from 1984 to 2005; however, some have alleged that it was 
abused. Further, the China Basic Medical Insurance (BMI) Authority also felt ﬁ nancial 
pressure due to the escalating use. Therefore, the China Health Insurance Research 
Association (CHIRA) decided to evaluate the value of coronary stenting as the evi-
dence for appropriate regulation. METHODS: This observational, prospective study 
involved 20 sites (13 cities). A total of 630 of 720 planned cases were recruited from
July 2005 to July 2006 with one year follow up. The study evaluated clinical and
economic value of stenting by collecting clinical, cost, and QoL data. Retrospective
data collected included reimbursement policy and actual claim data in 2005 and ﬁ rst 
half of 2006, to estimate the economic burden and budget impact and to analyze 
the cost-inﬂ uence factors. RESULTS: 1) There was generally not evident abuse in
PCI/stenting in the available data; 2) The effectiveness of PCI/stenting is favorable, 
with 1.43% complication, 0.98% death, 0.82% incidence of MI, and 1.79% of 
revascularization. All SEs are signiﬁ cantly lower than those seen published rates. The
QoL scores improved signiﬁ cantly (20, SF-36); 3) Stenting can gain $7100 per 
incremental QALY; 4) PCI fees are inﬂ uenced considerably by the number of diseased
vessels, co-morbidity, and reimbursement policy; 7) The price of PCI is lower than its 
cost, and thus it’s mainly reimbursed by pharmaceutical and device use; and 8) the 
economic burden of PCI was heavy in 2006. The out-of-pocket part of PCI was equal
to an employee’s average annual salary or twice that of a retiree’s pension. CONCLU-
SIONS: Stenting is cost effective with favorable QoL improvement. Therefore, it’s
worthwhile to further improve reimbursement regulations to release a patients’ eco-
nomic burden.
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OBJECTIVES: To construct a ﬂ exible Markov model allowing cost-effectiveness
analysis of different statin therapies over different time horizons in ACS patients in 
Germany. METHODS: A Markov model was designed to compare outcomes of 
intensive atorvastatin 80 mg versus standard simvastatin 20–40 mg treatment. Event 
rates for the ﬁ rst 5 years for MI, stroke, unstable angina, heart failure, revasculariza-
tion and cardiovascular death were derived from a post-hoc analysis of a subset of 
patients with recent ACS in the IDEAL study; extrapolation of event rates beyond the 
trial was based on risk-prediction equations from the Framingham study. Event and 
all-cause mortality were based on sources in literature. To estimate QALYs, utilities
were derived from the literature. Cost inputs were based on the German statutory 
health insurance perspective; patients’ co-payments were deducted. Costs of care for 
cardiovascular events were based on DRG costs for acute treatment, and on literature 
and expert panel results for subsequent costs. Univariate and probabilistic sensitivity
analyses were performed. All costs and beneﬁ ts were discounted by 5% annually, and
costs were reported in 2008 Euros. RESULTS: The base case used a one-year cycle
length, a lifetime time horizon, and a ﬁ ve-year treatment duration with high-dose
atorvastatin, after which all patients received simvastatin for life. For the base case, 
the incremental cost per life-year gained is €13,993, and the incremental cost per 
QALY gained is €14,168. At a threshold of €30,000 per QALY gained, sensitivity 
analysis predicted an 85% probability that atorvastatin 80 mg would be considered 
cost-effective compared with simvastatin 20–40 mg. CONCLUSIONS: The results can 
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only approximate real-life clinical practice; however, the carefully constructed model
and selection of input parameters, combined with data based directly on a post-hoc 
analysis of a clinical trial, make this a useful contribution to the debate regarding the 
incremental beneﬁ t of intensive statin therapy.
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OBJECTIVES: To assess the ﬁ nancial impact of a comprehensive cardiac care (CCC) 
program on total health care expenditures after an initial coronary event. METHODS:
This was a matched, retrospective analysis of a nurse- and pharmacist-managed CCC 
program that was designed to provide evidence-based lifestyle and medication support 
at the earliest opportunity after a coronary event. Patients with an incident occlusive 
CAD event between January 1999 and June 2004 were categorized into intervention
and comparator groups, respectively, by enrollment or never enrollment (No CCC)
into the CCC. Patients were matched 1:1 on chronic disease score (CDS) and 180-day
pre-coronary event (baseline) total health care expenditures. Pharmacy and medical 
utilization events were extracted from electronic administrative and claims databases.
Utilization events were collected after the initial coronary event until death, health 
plan termination, three years, or December 31, 2005, whichever came ﬁ rst (follow-up). 
Expenditure estimates from the Kaiser Permanente Decision Support System (in 2007 
dollars) were applied to utilization events. An intervention cost of $1/follow-up-day 
was applied to all CCC patients. Expenditures/day were modeled with adjustment 
for matching variables, patient characteristics, baseline expenditures, and intra-
correlations of matched patients. RESULTS: A total of 628 CCC patients were 
matched to 628 No CCC patients. Patients in the No CCC group were slightly older, 
more likely to be female, and to have had a myocardial infarction. Mean/median 
baseline expenditures and CDS were equivalent. During follow-up, 12 and 98 cardiac-
related deaths occurred in and mean/median total health care expenditures/day were 
$57/$30 and $159/$45 for the CCC and No CCC groups, respectively (both p 
0.001). After adjustment, CCC patients were associated with $103/day lower total 
health care expenditures (p  0.001; adjusted R-square  0.71 with log-transformed 
expenditures). CONCLUSIONS: Comprehensive and aggressive implementation of 
secondary cardiac prevention strategies with close monitoring and follow-up of CAD
patients is associated with reduced health care expenditures.
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OBJECTIVES: Venous thromboembolism (VTE) causes signiﬁ cant morbidity and
mortality and represents a huge health economic burden. Although enoxaparin has
some advantages over unfractioned heparin (UFH), both are recommended for pro-
phylaxis of VTE according to the guidelines from the Brazilian Medical Association. 
We present a tool to aid in selecting among similarly effective agents for VTE prophy-
laxis. The costs of UFH and enoxaparin to prevent venous thromboembolism in 
medical patients in the Brazilian treatment environment were compared. METHODS:
A decision model was used in a pharmacoeconomic comparison of enoxaparin and
UFH, each given for seven days, for the prophylaxis of VTE in medical patients. In
the model four main outcome pathways could follow prophylaxis: major bleeding, 
proximal deep venous thrombosis (with or without pulmonary embolism), distal deep 
venous thrombosis (DVT), and no DVT. False-negative or false-positive clinical diag-
noses of VTE were also taken into account. Probabilities of thromboembolic events 
and major bleeding were derived from published randomized clinical trials and meta-
analysis. Costs were calculated using the microcosting technique and the administra-
tive health care claims database of a major Brazilian Health Maintenance Organization 
from July, 2007 to June, 2008. The claims represented a full range of health plans 
levels at different hospitals. Only the costs related to the VTE prophylaxis and adverse 
events, acute VTE diagnosis, treatment and complications were considered. RESULTS:
Enoxaparin dominated UFH. There were cost savings of 74,121 Brazilians reais per
1,000 patients by using enoxaparin instead of UFH for prophylaxis of VTE. The
base-case analysis also demonstrated that the extra costs in the UFH group were
mainly related to the management of hemorrhagic adverse events. CONCLUSIONS:
This model of enoxaparin versus UFH for VTE prophylaxis in medical patients
showed that enoxaparin was less costly than UFH in overall expected costs from the
hospital perspective.
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OBJECTIVES: To determine the effect of a formulary change in the statin drug class 
on health outcomes and disease-speciﬁ c health care costs. METHODS: A retrospective
cohort design was implemented using pharmacy and medical claims data from a large
national employer group. Patients (n  330)with one or more claims for atorvastatin
or another statin during the six months prior to a formulary change on January 1, 
2006 were identiﬁ ed and evaluated. The formulary change was implemented for all
patients however, only those patients taking atorvastatin were affected. Cardiac-
related medical events (tests, doctor visits, outpatient facility visits, and acute cardio-
vascular events) and disease-speciﬁ c costs during the year following the formulary
change were measured. The impact of formulary change on cardiac-related medical 
events and disease-speciﬁ c costs were evaluated using multivariate analysis controlling 
for gender, age, comorbidity status, and drug indication (primary vs. secondary pre-
vention). RESULTS: Of the 330 patients, 180 (55%) used atorvastatin prior to the 
formulary change. After the implementation of the formulary change, 146 (81%) of 
patients switched to a preferred statin drug, 19 (10%) discontinued statin therapy, 
and 16 (9%) continued taking atorvastatin as a non-preferred drug. There were no
signiﬁ cant differences in the proportions of patients with cardiac tests (p  0.70), 
doctor’s visits (p  0.64), outpatient facility visits (p  0.52), or acute cardiovascular 
events (p  0.13) in the year after the formulary change between patients with pre-
formulary change claims for atorvastatin or another statin. There were no statistically
signiﬁ cant differences in health care costs among patients with pre-formulary change
claims for atorvastatin or another statin after adjustment for covariates (OR  0.89, 
95% CI: 0.41–1.92). CONCLUSIONS: Changing the formulary status of atorvastatin 
does not appear to adversely affect the total medical costs or utilization of cardiac-
related health care services.
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OBJECTIVES: Edaravone (Radicut), which was ﬁ rst approved in Japan in June 2001 
as a free radical scavenger, is used widely for the treatment of acute ischemic stroke 
in Japan. The purpose of this study was to estimate the economic impact of edaravone
therapy in Japan based on results of a meta-analysis of edaravone therapy for patients 
with lacunar infarction. METHODS: Japanese patients with lacunar infarction aged 
35 years or older were included in this analysis. We compared the economic impact 
of treatment for lacunar infarction between the edaravone group (E group) and the 
non-edaravone group (non-E group). For the basic information on patient status for
this analysis, we used previously published meta-analysis data on the modiﬁ ed Rankin 
Scale (mRS) distribution 1 month or more after the occurrence of lacunar infarction. 
Four types of costs were considered: hospitalization costs for lacunar infarction
therapy, nursing-care costs after hospital discharge, and productivity costs during 
hospitalization and due to work loss. RESULTS: The total costs per patient with 
lacunar infarction in the E and non-E groups were US$42,054 (1US$  92 JPY) and 
US$47,270, respectively, and the potential cost savings for using edaravone therapy
was estimated at US$5,216. The breakdown of total costs in the E and non-E groups, 
respectively were for hospitalization costs: US$10,215 (24.3%), and US$8,150
(17.2%), nursing-care costs: US$14,779 (35.1%), and US$18,256 (38.6%), decreased
productivity costs due to hospitalization: US$1,956 (4.7%), and US$2,065 (4.4%), 
and those due to work loss: US$15,105 (35.9%), and US$18,691 (39.5%). CONCLU-
SIONS: In this analysis, edaravone therapy for patients with lacunar infarction was 
ultimately a promising cost saving therapy compared with other therapies that did not
use edaravone, as it avoided nursing-care costs and productivity loss despite being
more expensive during acute treatment.
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OBJECTIVES: To assess the cost-effectiveness of oral rivaroxaban versus subcutane-
ous enoxaparin for prevention of venous thromboembolism (VTE) following total hip
replacement (THR) or total knee replacement (TKR) in Korea. METHODS: An eco-
nomic model was developed to evaluate the clinical and economic consequences of 
rivaroxaban versus enoxaparin, based on the RECORD2 and 3 randomized controlled 
trials. RECORD2 compared a 35-day course of rivaroxaban with a 12-day course of 
enoxaparin in THR, while RECORD3 compared 12-day courses of rivaroxaban and 
enoxaparin following TKR. In RECORD2, rivaroxaban reduced total VTE (compos-
ite: any deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality) 
by 79% and symptomatic VTE by 80% versus 12-day enoxaparin. In RECORD3,
rivaroxaban reduced total VTE by 49% and symptomatic VTE by 66% versus enoxa-
parin. Occurrence of major bleeding was similar with both agents. The model
accounted resource use according to primary research data and included direct medical 
costs from the Korean Health Insurance Review Agency. Utilities were derived from 
published literature and clinical and economic outcomes were discounted at a 5% 
annual rate in line with Korean guidelines. The model reported effectiveness outcomes
in quality-adjusted life years (QALYs) and costs in Korean Won (KRW) and was run 
over a ﬁ ve-year time horizon. RESULTS: In THR, rivaroxaban demonstrated per-
patient cost savings of KRW 40,803 versus enoxaparin and a gain of 0.0027 QALYs
per patient. In TKR, rivaroxaban reduced per-patient costs by KRW 27,692 and 
resulted in a gain of 0.0019 QALYs per patient. Cost savings in the rivaroxaban arm 
